Literature DB >> 28319455

Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.

Audrey Mauguen1,2, Stefan Michiels3,4, Virginie Rondeau1,2.   

Abstract

Clinical trial duration may be a concern in clinical research, especially in cancer trials where the endpoint is overall survival. A surrogate endpoint can be used as an auxiliary variable to analyze the treatment effect earlier. At an early time point, the high number of censored observations can be compensated by the imputation of the unobserved deaths times. We propose to use predictions of the risk of death from a joint model for a recurrent event and a terminal event, which account for disease relapse information. Two imputation methods were compared: sampling from the estimated parametric distribution of the survival time and sampling using its nonparametric estimation. The treatment effect and its standard error were estimated via multiple imputations. The performances of the two methods were compared in terms of bias in the estimates, standard errors, and coverage probability. Both methods were then retrospectively applied to two randomized clinical trials studying the effect of adjuvant chemotherapy in breast cancer patients.

Entities:  

Keywords:  Cancer; joint model; multiple imputation; prediction; randomized clinical trial; surrogate endpoint; survival

Mesh:

Year:  2017        PMID: 28319455     DOI: 10.1080/10543406.2017.1295249

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  1 in total

1.  Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".

Authors:  Stefan Michiels; Everardo D Saad; Marc Buyse
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.